Immupharma PLC New Corporate Website
July 09 2012 - 2:00AM
RNS Non-Regulatory
TIDMIMM
Immupharma PLC
09 July 2012
FOR IMMEDIATE RELEASE 9 July 2012
RNS REACH
IMMUPHARMA LAUNCHES NEW CORPORATE WEBSITE
PROVDING GREATER CLARITY ON LUPUZOR, CANCER AND ITS DEVELOPMENT
PIPELINE
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the
specialist drug development company has today launched its new
corporate website www.immupharma.com as part of its continued focus
on improving how it communicates to investors, collaborators and
potential licensing partners.
The new ImmuPharma website provides more detailed information
about its two platform technologies and the Company's five lead
compounds in development, each representing a potentially
significant breakthrough in its field. This includes its lead
product Lupuzor(TM), for the treatment of Lupus, which has recently
received US FDA approval to enter Phase III with a Special Protocol
Assessment and Fast Track designation and its cancer programme
IPP-204106 which has a novel mechanism of action, aimed at
preventing angiogenesis as well as proliferationand which was in
May 2011 chosen to feature on the front cover of 'Cancer Research',
the prestigious medical journal of the American Association for
Cancer Research.
The website also provides more detail on ImmuPharma's key
collaborator, Europe's largest fundamental research institution,
the Centre National de la Recherche Scientifique (National Center
for Scientific Research) or CNRS.
The website also includes an email alert service, for which
shareholders are encouraged to register.
Dimitri Dimitriou, ImmuPharma's Chief Executive Officer,
commented:
"We are seeking to provide improved information in this new
website, which includes more detailed content to give a
comprehensive and accessible overview of ImmuPharma's investment
strategy, key assets including our discovery pipeline and the
collaborators we work with such as CNRS."
For further information please contact:
ImmuPharma PLC
Dimitri Dimitriou, Chief Executive
Officer +44 20 7152 4080
Lisa Baderoon, Head of Investor
Relations +44 7721 413 496
Buchanan + 44 20 7466 5000
Mark Court
Website designed by Fruit Design
www.fruit-design.co.uk
Notes to Editors
ImmuPharma is focusing on developing novel medicines with high
sales potential in specialist markets with serious unmet need.
ImmuPharma has five drug candidates in development, two platform
technologies and approximately 70 patents. The Company's most
advanced drug candidate, Lupuzor(TM) a potential blockbuster drug
for Lupus, a chronic autoimmune disease has recently received the
approval from the US FDA to enter phase III with a Special Protocol
Assessment and "Fast Track" designation. ImmuPharma was founded and
is led by a commercially focused Board and management team with
extensive experience. www.immupharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABVLLBLDFFBBE
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024
